GLMD (Galmed Pharmaceuticals Ltd.) Quarterly EPS earnings growth

Corporate company logo of Galmed Pharma (GLMD)

Price action depends on biological data and the availability of R&D capital rather than economic cycles. Galmed Pharmaceuticals (GLMD) bases its business on combating liver fibrosis via small molecules, utilizing optimized supplies of biochemical raw materials. The quarterly EPS growth rate demonstrates the issuer's real economics, with the value of 43.80 serving as the current indicator for this metric.

galmedpharma.com (GLMD) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 09/10/2026

GLMD (Galmed Pharmaceuticals Ltd.): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Fundamental valuation:Galmed Pharmaceuticals
Flagship merchandise of galmedpharma.com

This indicator calculates the quarterly dynamics of net profit per share, reflecting capital management efficiency and the business's ability to generate value. For Galmed Pharmaceuticals (GLMD), which is currently in the clinical trial stage without stable revenue, the quarterly EPS growth rate serves as a marker of financial stability and the cash burn rate prior to drug commercialization.